Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol

by Olga B. Baltzersen, Herbert Y. Meltzer, Vibe G. Frokjaer, Vibe G. Frokjaer, Jayachandra M. Raghava, Jayachandra M. Raghava, Lone Baandrup, Lone Baandrup, Birgitte Fagerlund, Henrik B.W. Larsson, H. Christian Fibiger, Birte Y. Glenthøj, Birte Y. Glenthøj, Gitte M. Knudsen, Gitte M. Knudsen, Bjørn H. Ebdrup, Bjørn H. Ebdrup
Published 2020-04-01

Striatal Volume Increase After Six Weeks of Selective Dopamine D2/3 Receptor Blockade in First-Episode, Antipsychotic-Naïve Schizophrenia Patients

by Helle G. Andersen, Helle G. Andersen, Jayachandra M. Raghava, Jayachandra M. Raghava, Claus Svarer, Sanne Wulff, Louise B. Johansen, Patrick K. Antonsen, Patrick K. Antonsen, Mette Ø. Nielsen, Mette Ø. Nielsen, Egill Rostrup, Anthony C. Vernon, Anthony C. Vernon, Lars T. Jensen, Lars H. Pinborg, Birte Y. Glenthøj, Birte Y. Glenthøj, Bjørn H. Ebdrup, Bjørn H. Ebdrup
Published 2020-05-01

No Effects of Cognitive Remediation on Cerebral White Matter in Individuals at Ultra-High Risk for Psychosis—A Randomized Clinical Trial

by Tina D. Kristensen, Tina D. Kristensen, Bjørn H. Ebdrup, Bjørn H. Ebdrup, Bjørn H. Ebdrup, Carsten Hjorthøj, Carsten Hjorthøj, René C. W. Mandl, René C. W. Mandl, Jayachandra M. Raghava, Jayachandra M. Raghava, Jens Richardt M. Jepsen, Jens Richardt M. Jepsen, Birgitte Fagerlund, Birgitte Fagerlund, Louise B. Glenthøj, Louise B. Glenthøj, Christina Wenneberg, Christina Wenneberg, Kristine Krakauer, Christos Pantelis, Christos Pantelis, Birte Y. Glenthøj, Birte Y. Glenthøj, Merete Nordentoft, Merete Nordentoft, Merete Nordentoft
Published 2020-08-01